Propensity score matching analysis for adverse events of EUS-guided biliary drainage in advanced elderly patients (PEACE study)

Takeshi Ogura, Hirotoshi Ishiwatari, Nao Fujimori, Eisuke Iwasaki, Kazuma Ishikawa, Tatsunori Satoh, Junichi Kaneko, Junya Sato, Takamasa Oono, Kazuhide Matsumoto, Seiichiro Fukuhara, Atsuto Kayashima, Akitoshi Hakoda and Kazuhide Higuchi

Abstract
Background: Several studies have suggested that elderly patients, as well as younger patients, can be safely treated using endoscopic retrograde cholangiopancreatography (ERCP). However, endoscopic ultrasound-guided biliary drainage (EUS-BD) has not been clinically evaluated for very elderly patients. The present multicenter, retrospective study aimed to determine the safety of EUS-BD for advanced elderly patients.

Method: Patients who underwent EUS-BD during this period were retrospectively enrolled, and they were divided into two groups based on age: group A (age < 75 years) and group B (age ≥ 75). In this study, capnographic monitoring was used only for elderly patients (age ≥ 75 years).

Results: A total of 271 patients who underwent EUS-BD were enrolled in this study (group A = 177, group B = 94). The types of adverse events that were associated with EUS-BD was observed in 38 patients, and they did not differ significantly between two groups (p = 0.855). This result was confirmed after propensity score matching (p = 0.510). Adverse events were associated with sedation after propensity score matching; hypoxemia (p = 0.012) and severe hypoxemia (p = 0.003) were significantly higher in group A compared with group B. According to logistic regression analysis, monitoring (non-capnography) was also only risk factor (odds ratio: 0.317, 95% confidence interval: 0.143–0.705; p = 0.005) for sedation-related adverse events.

Conclusion: In conclusion, EUS-BD could be safety performed in advanced elderly patients, the same as in younger patients. Also, capnographic monitoring might be helpful in case of sedation by a gastroenterologist in a non-intubated patient. Further prospective, randomized studies are needed to confirm these conclusions.

Keywords: adverse event, elderly, EUS, EUS-guided biliary drainage, sedation

Received: 23 November 2021; revised manuscript accepted: 15 March 2022.
for EUS-BD might be expanded in the near future.

The World Health Report 2019 highlighted the accelerated aging of the global population because the number of people aged ≥60 years is increasing.14 Several studies have suggested that elderly patients, as well as younger patients, can be safely treated using ERCP.15–17 However, EUS-BD has not been clinically evaluated for very elderly patients. The present multicenter, retrospective study aimed to determine the safety of EUS-BD for advanced elderly patients.

**Patients and methods**

This retrospective study was carried out at Osaka Medical College, Shizuoka Cancer Center, Kyushu University Hospital, and Keio University Hospital between April 2014 and April 2019. Patients who underwent successful EUS-BD during this period were retrospectively enrolled, and they were divided into two groups based on age: group A (age <75 years) and group B (age ≥75). All enrolled patients provided written, informed consent to participate in EUS-BD procedures associated with the study. This study was approved by the institutional review boards at each hospital (No 2873).

**Technical tips for EUS-guided biliary drainage**

Target lesions such as the intrahepatic and extrahepatic bile ducts or the gallbladder were identified using a GF-UCT260 echoendoscope (Olympus Optical, Tokyo, Japan). After puncture, contrast medium was injected through a 19 G needle. A 0.025-inch guidewire was inserted into the target lesions. A fistula was dilated using a balloon catheter, mechanical dilator, or electrocautery dilator. A partially covered (10 mm × 10 cm or 12 cm Niti-S Biliary Covered Stent (TaeWoong Medical, Seoul, South Korea) or Type IT dedicated plastic stent (Gadelius Medical Co, Ltd, Tokyo, Japan) for EUS-HGS or a fully covered, self-expandable 10 mm × 6 cm BONA metal stent (Standard Sci Tech Inc., Seoul, Korea) or double pig plastic stent for EUS-CDS or GBD was deployed. Because a substantial amount of infected bile juice leaked from the fistula before stent deployment during EUS-BD, antibiotics were given for up to 2 days. If laboratory findings indicated inflammation suggestive of bile peritonitis, continuous antibiotics were administered. Whether stents had migrated or become shortened was assessed using computed tomography on the following day. Oral intake was started if the stent position was appropriate, and infection was not found. The stent position was reconfirmed 1 month after deployment based on computed tomography and laboratory findings. If stent migration was complicated, percutaneous transhepatic biliary drainage (PTBD) may be first considered. If PTBD is failed, surgical treatment may be also considered.

**Details of sedation and monitoring**

EUS-BD was mainly performed with the patient under deep sedation. The achievement of deep sedation was determined according to the American Society of Anesthesiologists18 or Ramsay sedation scores (4 or 5).19 Sedation was performed by endoscopists and using dexmedetomidine, midazolam, diazepam, pethidine, or pentazocine. Endoscopists initiated all sedation with 3–5 mg each of midazolam and pentazocine. In patients who underwent deep sedation using dexmedetomidine (anesthesia induction dose 6 μg/kg, maintenance dose 0.2 μg/kg/h), diazepam (5 mg) and pethidine (35 mg) were administered. The depth of sedation was evaluated 2 min thereafter. If deep sedation was not achieved, the appropriate dose of each drug was given additionally. The echoendoscope was inserted after deep sedation was confirmed. The appropriate dose of each drug was also administered as required during EUS-BD. Pulse oximetry (SpO2), heart rate, respiratory rate, and blood pressure were monitored during EUS-BD procedures along with clinical observation. All patients in this group were fitted with a nasal cannula for oxygen administration (2–3 L/min). In this study, a Capnostream 20 capnograph (Covidien Sales LLC, Mansfield, MA, USA) was used only for elderly patients (age ≥75 years). The Capnostream 20 capnograph continuously displayed end-tidal CO₂ (etCO₂), respiratory rate, heart rate, and SpO₂ on a surveillance monitor. A mouthpiece attached to a nasal cannula supplied O₂ and measured etCO₂ in group B. These patients also received oxygen. Respiratory rates determined by capnography every minute were stored on the monitor. Oxygen supplementation was increased if hypoxemia developed in either group during EUS-BD. Appropriate treatment, such as patient stimulation, reduction of sedatives, chin lifts, jaw thrust maneuvers, or bag-valve-mask ventilation, was
administered if the patient developed severe hypoxemia or apnea. Also, echoendoscope intubation was considered. This procedure was applied if tract dilation was not performed. An alert was set up when etCO$_2$ $<$ 15 mmHg continued for 10 s in patients monitored by capnography, and when SpO$_2$ $<$ 90 was observed in patients monitored by standard monitoring. Also, if hypotension was caused by sedation, increasing infusion rates or pressor agents were provided.

**Definitions and statistical analysis**

The primary endpoint of this study was a comparison of adverse events associated with EUS-BD between groups A and B. As the secondary endpoint, adverse events associated with sedation were evaluated.

The physical condition of the patients before EUS-BD was evaluated according to the Eastern Cooperative Oncology Group (ECOG) performance status (PS). Bile peritonitis was considered if laboratory examinations showed evidence of inflammation, and there was abdominal pain and a fever. Hypoxemia was defined as continuous SpO$_2$ $\leq$ 90% for at least 15 s, and SpO$_2$ $\leq$ 85% that continued for $>$ 15 s was considered severe hypoxemia. Apnea was considered when the etCO$_2$ or the respiratory rate was 0 for at least 30 s. Procedural duration was determined from the time of echoendoscope insertion to that of stent deployment. The data collection was performed by auto-recording system in capnographic monitoring, and by medical record during EUS-BD.

Survival rate at 3, 6, and 12 months was taken as the time from the day of EUS-BD to the death of the patient. Stent patency was also measured from the stent deployment to stent dysfunction, patient’s death, or lost follow-up. The severity of adverse events was graded according to the American Society for Gastrointestinal Endoscopy lexicon.

Descriptive data are presented as medians (IQR), means [± standard deviation (SD)], or numbers (n, %). The two groups were compared using analysis of variance for continuous factors, Kruskal–Wallis tests for numbers of events, and Pearson chi-square test or Fisher’s exact tests for categorical factors. Survival curves for OS were estimated from Kaplan–Meier curves. Differences with $p < 0.05$ were considered significant.

**Results**

**Baseline characteristics**

Table 1 shows the baseline characteristics of the patients. A total of 271 patients who underwent EUS-BD were enrolled in this study. Of the 217 patients, 177 were assigned to group A (median age, 67 years; range, 36–74 years; male, n = 105), and 94 were assigned to group B (median age, 80 years; range, 75–98 years; male, n = 55). ECOG PS was significantly worse in group B ($p < 0.001$). The choice of treatment was mainly EUS-BD for malignant diseases, and the two groups did not differ significantly. Group B was more likely to have comorbidities, such as cardiovascular comorbidities ($p < 0.001$), than group A.

Mean follow-up period was 190.1 ± 318.3 days (group A versus group B; 178.4 ± 324.9 versus 178.4 ± 307.0 days, $p = 0.63$). As shown in Figure 1, survival rate at 3, 6, and 12 months [(95% confidence interval (CI)] was 64.6% (57.1%–73.1%), 53.3% (45.3%–62.7%), and 30.3% (22.7%–40.4%) in group A, respectively. Survival rate at 3, 6, and 12 months (95% CI) was 65.0% (54.1%–78.0%), 56.5% (44.9%–71.0%), and 48.7% (36.6%–64.7%) in group B, respectively. Figure 2 showed Kaplan–Meier curves of stent patency. Stent patency at 3, 6, and 12 months (95% CI) was 92.9% (88.2%–97.8%), 82.8% (74.4%–92.1%), and 57.8% (41.6%–80.4%) in group A, respectively, and 96.8% (90.8%–100%), 84.3% (71.1%–99.9%), and 39.2% (21.6%–71.0%) in group B, respectively, with no significant difference.
Table 1. Patient’s characteristics.

| Characteristics          | Entire cohort (n = 271) | Propensity score matching cohort (n = 150) |
|--------------------------|-------------------------|------------------------------------------|
|                          | Group A (n = 177)       | Group B (n = 94)                        | p value | Group A (n = 75) | Group B (n = 75) | p value |
| Age (year, median [IQR]) | 67 [36–74]              | 80 [75–98]                              | <0.0001 | 68 [45–74]       | 80 [75–97]       | <0.0001 |
| Gender [male:female]     | 105:72                  | 55:39                                   | 0.8971  | 46:29            | 45:30            | 0.8673  |
| ECOG PS, % (n)           |                         |                                         | <0.0001 |                |                | 0.1726  |
| 0                        | 25.4 (45)               | 5.3 (5)                                 |         | 16 (12)          | 6.7 (5)          |         |
| 1                        | 45.7 (81)               | 42.5 (40)                               |         | 40 (30)          | 53.3 (40)        |         |
| 2                        | 17.5 (31)               | 20.2 (19)                               |         | 25.3 (19)        | 18.6 (14)        |         |
| 3                        | 10.1 (18)               | 31.9 (30)                               |         | 17.3 (13)        | 21.3 (16)        |         |
| 4                        | 1.1 (2)                 | 0 (0)                                   |         | 13.3 (11)        | 0 (0)            |         |
| Primary disease, n       |                         |                                         | <0.0001 |                |                | 0.4353  |
| Malignancy               | 154                     | 63                                      |         | 60               | 56               |         |
| Benign                   | 23                      | 31                                      |         | 15               | 19               |         |
| Number of comorbidity    | 1 [0–5]                 | 2 [0–7]                                 | <0.0001 | 1 [0–4]          | 2 [0–7]          | 0.4670  |
| Kinds of comorbidity, n  |                         |                                         |         |                |                |         |
| Cardiovascular disease    | 43                      | 52                                      | <0.0001 | 30              | 35              | 0.4100  |
| Diabetes mellitus        | 24                      | 30                                      | 0.0003  | 28              | 32              | 0.5050  |
| Pulmonary disease        | 9                       | 6                                       | 0.6564  | 1               | 2               | 0.5598  |
| Renal disease            | 9                       | 7                                       | 0.4323  | 2               | 3               | 0.6492  |
| Others                   | 35                      | 50                                      | <0.0001 | 22              | 24              | 0.7232  |
| Baseline serum bilirubin, mg/dl [mean ± SD] | 6.55 ± 6.31 | 5.69 ± 6.15 | 0.2891 | 6.12 ± 6.22 | 6.46 ± 6.34 | 0.7458 |
| Baseline serum WBC, /μl [mean ± SD] | 7599.7 ± 4575.3 | 10021.1 ± 21499.1 | 0.1512 | 7772.5 ± 3433.3 | 7222.7 ± 3778.8 | 0.3525 |
| Baseline serum CRP, mg/L [mean ± SD] | 4.76 ± 5.05 | 7.02 ± 7.64 | 0.0043 | 5.17 ± 4.87 | 5.84 ± 7.30 | 0.5056 |
| Kinds access route of EUS-BD, % (n) |                        |                                         | 0.3120  |                |                | 0.5237  |
| Stomach                  | 80.8 (143)              | 75.5 (71)                               |         | 80 (60)         | 84 (63)         |         |
| Duodenum                 | 19.2 (34)               | 25.5 (23)                               |         | 20 (15)         | 16 (12)         |         |
| Kinds of dilation devices, n |                     |                                         | <0.0001 |                |                | 0.8621  |
| Balloon                  | 88                      | 56                                      |         | 41              | 44              |         |
| Electrocautery dilator   | 37                      | 3                                       |         | 4               | 4               |         |
| Mechanical dilator       | 12                      | 2                                       |         | 4               | 2               |         |

(Continued)
Of the EUS-BD procedures, transgastric biliary drainage such as EUS-HGS was more frequent, although the kinds of access routes for EUS-BD did not differ significantly between the groups. Balloon dilation was usually used for fistula dilation in both groups. In addition, a metal stent was mainly used in both groups. Procedural duration was significantly shorter in group B (29.1 ± 20.1 min versus 20.5 ± 13.0 min; \( p < 0.001 \)). After propensity score matching, 75 patients were collected in each group. All factors were not significant differences between two groups except age factor.

**Procedure-related adverse events**

Table 2 shows the procedure-related adverse events. Adverse events were observed in 38 patients (14%). The types of adverse events that were associated with EUS-BD in 24 patients were bile peritonitis (groups A and B: \( n = 15 \) and \( n = 9 \), respectively), bleeding (groups A and B: \( n = 3 \) and \( n = 1 \), respectively), pancreatitis (groups A and B: \( n = 3 \) and \( n = 2 \), respectively), biloma (groups A and B: \( n = 1 \) and \( n = 1 \), respectively), and sepsis (groups A and B: \( n = 2 \) and \( n = 0 \), respectively), and almost all patients were treated conservatively. There were no significant differences between two groups (group A versus group B = 13.6% versus 14.9%; \( p = 0.855 \)). In addition, after propensity score matching, rate of adverse events did not differ among two group (\( p = 0.510 \)). In this study, risk factors associated procedure-related adverse events was not detected after logistic regression analysis. Late adverse events were observed in 27 patients [cholangitis (\( n = 25 \)], hepatic artery rupture (\( n = 2 \)].

![Figure 1. The Kaplan–Meier curves of survival rate.](image1)

![Figure 2. The Kaplan–Meier curves of stent patency.](image2)

**Sedation outcomes**

Table 3 shows the outcomes of sedation during EUS-BD. Midazolam was the main drug used for sedation, followed by dexametomidine and flunitrazepam. As analgesic drugs, pentazocine was the main drug, followed by pethidine. The mean doses of midazolam (5.67 ± 3.13 versus 5.93 ± 1.52 mg;
Adverse events were associated with sedation in 67 (24.7%) patients, among whom 48 and 19 were in groups A and B, respectively. There were

Table 2. Procedure-related adverse events.

| Characteristics   | Entire cohort (n=271) | Propensity score matching cohort (n=150) |
|-------------------|-----------------------|----------------------------------------|
|                   | Group A (n=177)       | Group B (n=94)   | p value | Group A (n=75) | Group B (n=75) | p value |
| Total adverse events, n | 24                    | 14               | 0.855    | 10             | 14             | 0.510    |
| Bile peritonitis  | 15                    | 9                | 5        | 9              |
| Bleeding          | 3                     | 1                | 2        | 1              |
| Pancreatitis      | 3                     | 2                | 1        | 2              |
| Biloma            | 1                     | 1                | 1        | 1              |
| Stent migration   | 0                     | 0                | 0        | 0              |
| Sepsis            | 2                     | 0                | 1        | 0              |

Table 3. Sedation outcomes.

| Characteristics   | Entire cohort (n=271) | Propensity score matching cohort (n=150) |
|-------------------|-----------------------|----------------------------------------|
|                   | Group A (n=177)       | Group B (n=94)   | p value | Group A (n=75) | Group B (n=75) | p value |
| Kinds of sedation, n |                       |                       |         |                |                |         |
| Dexmedetomidine   | 31                    | 0                     | 0        | 0              | 0              | 0        |
| Flunitrazepam     | 3                     | 0                     | 0        | 0              | 0              | 0        |
| Midazolam         | 174                   | 94                    | 75       | 75             |
| Kinds of analgesics, n |                   |                       |         |                |                |         |
| Pentazocine       | 121                   | 94                    | 74       | 75             |
| Pethidine         | 45                    | 0                     | 1        | 0              |
| Fentanyl          | 2                     | 0                     | 0        | 0              |
| Mean dose of midazolam [± SD, mg] | 5.67 ± 3.13 | 5.93 ± 1.52 | 0.3189 | 5.97 ± 1.85 | 5.89 ± 1.56 | 0.7932 |
| Mean dose of pentazocine [± SD, mg] | 8.24 ± 2.81 | 7.42 ± 0.57 | 0.6631 | 5.74 ± 3.55 | 5.24 ± 1.00 | 0.4482 |
| Total adverse events, n [%] |                  |                       |         |                |                |         |
| Hypoxemia         | 28                    | 6                     | 0.032    | 15             | 4              | 0.012    |
| Severe hypoxemia  | 16                    | 4                     | 0.222    | 15             | 1              | 0.003    |
| Apnea             | 1                     | 1                     | 1.000    | 1              | 1              | 1.000    |
| Hypotension       | 3                     | 8                     | 0.002    | 1              | 5              | 0.210    |

SD, standard deviation.

*p=0.319) and pethidine (8.24 ± 2.81 versus 7.42 ± 0.57 mg; *p*=0.663) did not differ significantly between the groups.
significant differences between groups A and B in hypoxemia (28 (15.8%) \textit{versus} 8 (6.4%), respectively; \(p = 0.032\)). However, there were no significant difference in severe hypoxemia (16 (9.0%) \textit{versus} 4 (4.3%), respectively; \(p = 0.222\)), and in apnea (1 (0.5%) \textit{versus} 1 (1.1%), respectively; \(p = 1.00\)). Hypotension was observed frequently in group B [3 (1.7%) \textit{versus} 8 (8.5%), respectively; \(p = 0.020\)]. Patients with hypoxemia and severe hypoxemia were treated by increasing oxygen supplementation, stimulation, reducing sedatives, chin lifts, and jaw thrust maneuvers. On the other hand, echoendoscope intubation had to be interrupted to treat patients who developed apnea in each group. Hypotension was treated appropriately. On the other hand, after propensity score matching, hypoxemia (\(p = 0.012\)) and severe hypoxemia (\(p = 0.003\)) were significantly higher in group A compared with group B. Table 4 showed risk factors for sedation-related adverse events. Before propensity score matching, monitoring (non-capnography) was only risk factor for sedation-related adverse events [odd ratio (OR): 0.439, 95\% CI: 0.219–0.880; \(p = 0.020\)]. In addition, after propensity score matching, monitoring (non-capnography) was also only risk factor (OR: 0.317, 95\% CI: 0.143–0.705; \(p = 0.005\)).

### Discussion

Table 5 shows recent largest studies regarding EUS-guided transhepatic biliary drainage.\textsuperscript{13,23–27} According to these studies, technical rate was 97\%–100\%, and clinical success rate was 76\%–94\%. Rate of adverse events was 3\%–23\%. These results were similar to our study. Therefore, procedure results of our study might be reliable. The present study produced two significant findings. One is that EUS-BD was equally safe for younger and elderly patients. Although the feasibility of EUS-BD for elderly patients has not been investigated, several studies have assessed ERCP for elderly patients. Fritz \textit{et al.}\textsuperscript{15} assessed the safety of 724 ERCP procedures in 502 elderly patients by evaluating clinical differences including adverse events between younger (age < 80 years, \(n = 405\)) and elderly (age \(\geq 80\) years, \(n = 97\)) patients. Rates of chronic concomitant disease complications were significantly higher in the elderly group than in the younger group (average rate per patient: 1.08 \textit{versus} 0.57; \(p < 0.001\)). Mortality rates (1.03\% \textit{versus} 0.25\%), rates of adverse events such as bleeding, post-ERCP pancreatitis, or perforation (1.03\% \textit{versus} 0.25\%, respectively) did not differ significantly between the groups. Han \textit{et al.}\textsuperscript{16} evaluated the safety of therapeutic ERCP in elderly (age \(\geq 80\) years; \(n = 312\)) and younger (age < 65 years; \(n = 312\)) patients. Although concomitant disease was more frequent in the elderly patients (70.5\% \textit{versus} 29.8\%, respectively; \(p < 0.01\)), rates of technical success (94.9\% \textit{versus} 97.4\%; \(p = 0.096\)), procedure-related adverse events (4.8\% \textit{versus} 5.8\%, respectively; \(p = 0.592\)), and post-ERCP pancreatitis (1.3\% \textit{versus} 2.9\%, respectively; \(p = 0.262\)) did not differ significantly between the groups. Therefore, ERCP might be

### Table 4. Risk factors for sedation-related adverse events.

| Characteristics                  | Entire cohort (\(n = 271\)) | Propensity score matching cohort (\(n = 150\)) |
|----------------------------------|------------------------------|-----------------------------------------------|
|                                  | Odds ratio 95\% CI p value   | Odds ratio 95\% CI p value                     |
| Monitoring (capnography)         | 0.439 0.219–0.880 0.020      | 0.317 0.143–0.705 0.005                         |
| Primary disease (malignant)      | 1.191 0.557–2.546 0.653      | 1.722 0.651–4.558 0.274                         |
| Number of comorbidity (\(\geq 2\)) | 1.657 0.915–3.000 0.096     | 1.692 0.796–3.597 0.171                         |
| Performance status (\(\geq 2\)) | 1.360 0.747–2.477 0.315      | 1.400 0.661–2.962 0.380                         |
| Procedure time (\(\geq 25\)min) | 0.562 0.296–1.066 0.078      | 0.582 0.242–1.400 0.227                         |
| Baseline serum bilirubin (\(\geq 5\)mg/dl) | 1.007 0.558–1.816 0.982 | 1.054 0.497–2.233 0.891                                 |
| Baseline serum WBC (\(\geq 12000/\mu l\)) | 0.949 0.391–2.302 0.908 | 1.435 0.464–4.439 0.531                                 |
| Baseline serum CRP (\(\geq 5\)mg/L) | 0.843 0.457–1.554 0.584 | 1.579 0.746–3.341 0.232                                 |

CI, confidence interval; CRP, C-reactive protein; WBC, white blood cell.
safe for elderly patients. However, compared with ERCP, EUS-BD has not been established as a treatment for pancreatobiliary disease. In addition, EUS-BD might require deeper sedation because the thin bile duct should be punctured, and stent deployment is needed across the abdominal cavity. Based on this background, the present multicenter, retrospective study evaluated the technical feasibility of EUS-BD for patients aged \( \geq 75 \) years and found no significant differences compared with younger patients. In addition, this fact was not changed after propensity score matching.

The other significant finding was that the total adverse event rate associated with sedation during EUS-BD was not frequent in elderly patients compared with younger patients.

Capnographic monitoring can help ensure the safety of endoscopic treatment such as ERCP and percutaneous endoscopic gastrostomy. Because deep sedation is needed for advanced endoscopic procedures, the risk of cardiopulmonary adverse events during procedures should be considered. Elderly patients in particular can easily develop cardiovascular events during ERCP under deep sedation. However, the clinical impact of capnographic monitoring on EUS-BD is unclear. Capnographic monitoring in gastrointestinal endoscopy is clinically useful, according to previous studies. Peveling-Oberhag et al. conducted a prospective, controlled, randomized evaluation of the clinical usefulness of capnography monitoring during percutaneous gastrostomy placement (PEG). They randomly assigned 150 patients to receive capnography or standard monitoring. Compared with capnography monitoring, episodes of hypoxemia (57% versus 41%; OR: 0.29, 95% CI, 0.15–0.57; \( p = 0.0005 \)) and severe hypoxemia (28% versus 20%; OR: 0.35, 95% CI: 0.17–0.73; \( p = 0.0008 \)) were significantly more prevalent in the group that received standard monitoring. Qadeer et al. conducted a prospective, randomized trial that included 247 patients with or without capnography monitoring during ERCP. The number of patients in the blinded and open arms who developed hypoxemia was 132 (69%) and 69 (46%), respectively (\( p < 0.001 \)). The ratio of severe hypoxemia and apnea in these arms was 31% versus 15% (\( p = 0.004 \)) and 63% versus 41% (\( p < 0.001 \)), respectively. As in other studies, the present study found that elderly patients generally have multiple comorbidities.

### Table 5. Summary of previous studies (recent years, including 30 over cases).

| Number of patients, \( n \) | Technical success rate, % (\( n \)) | Clinical success rate, % (\( n \)) | Procedure time, min | Type of stent | Adverse event, % (\( n \)) |
|-----------------------------|-------------------------------------|-----------------------------------|---------------------|---------------|----------------------------|
| Minaga et al.\(^{23}\)      | 30                                  | 97(29/30)                         | 76(22/29)           | Plastic stent, CSEMS | 9, [Bile peritonitis (1)]   |
| Sportes et al.\(^{24}\)     | 31                                  | 100(31/31)                        | 81(25/31)           | FCSEMS         | 3, [Severe sepsis (2), Bile leak (2), Bleeding and death (1)] |
| Oh et al.\(^{25}\)          | 129                                 | 93(120/129)                       | 88(105/120)         | Plastic stent, FCSEMS | 16 [Bacteremia (6), Bleeding (5), Bile peritonitis (4), Intrahepatic stent migration (3)] |
| Honjo et al.\(^{26}\)       | 49                                  | 100(49/49)                        | N/D                 | PCSEMS         | 17, [Abdominal pain (6), Bleeding (5)] |
| Paik et al.\(^{13}\)        | 32                                  | 97(31/32)                         | 84(26/31)           | PCSEMS         | 3, [Cholangitis (1)]       |
| Nakai et al.\(^{27}\)       | 110                                 | 100(110/110)                      | 94(93/110)          | PCSEMS         | 23, [Transient fever (10), abdominal pain (4), peritonitis (4), cholangitis (3), pseudoaneurysm (1), abscess (1), hemobilia (1), cholecystitis (1)] |

CSEMS, covered self-expandable metal stent; FCSEMS, fully covered self-expandable metal stent; PCSEMS, partially covered self-expandable metal stent.
which increase risk when undergoing not only treatment, but also sedation. Therefore, in this study, we use capnographic monitoring to detect early respiratory failure in elderly patients. Indeed, adverse events associated with sedation such as hypoxemia and severe hypoxemia were significantly more prevalent in younger than in elderly patients ($p=0.012$ and $p=0.003$, respectively), although the mean doses of sedation did not differ in the present study. This might be based on an early warning system for hypoxemia and apnea, which is caused by a decrease in etCO$_2$. In addition, monitoring (non-capnography) was only risk factor for sedation-related adverse events according to our logistic regression analysis. This result should be confirmed by randomized trial between capnography and standard monitoring.

There are several limitations of the present study. First, this was a retrospective, non-randomized study. Therefore, sample size setting might not be adequate. Second, data collection in monitoring, although auto-recording system was used in capnographic monitoring, on-time recording was not able to performed in standard monitoring. These facts might be a critical limitation such as recall bias of this study; therefore, a randomized trial with strict criteria is needed to verify the present results. Third, because of retrospective nature, the diameter of the intrahepatic bile duct was not able to evaluated. This fact may influence procedure time because bile duct puncturing is easy in case of large diameter of the intrahepatic bile duct. In our study, procedure time was significantly shorter in group B. This might be based on the fact that older patient was complicated with more co-morbidities. Therefore, indications of EUS-guided transhepatic may not suffer any concerns. Therefore, compared with group A, the diameter of the intrahepatic bile duct might be larger in group B. In addition, several factors such as ascites or liver atrophy may be fewer in group B. Although these factors were not evaluated because of retrospective nature as mentioned above, after propensity score matching analysis, procedure time was same between two groups. Finally, invasive procedures such as EUS-guided transhepatic biliary drainage may be performed under general anesthesia in many countries. In our study, all patients underwent EUS-guided transhepatic biliary drainage under non-general anesthesia. Therefore, our findings might be limited for patients with non-general anesthesia.

In conclusion, EUS-BD could be safety performed in advanced elderly patients, the same as in younger patients. Also, capnographic monitoring might be helpful in case of sedation by a gastroenterologist in a non-intubated patient. Further prospective, randomized studies are needed to confirm these conclusions.

**Author contributions**

**Takeshi Ogura:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Software; Writing – original draft.

**Hirotoshi Ishiwatari:** Validation; Writing – review & editing.

**Nao Fujimori:** Validation; Writing – review & editing.

**Eisuke Iwasaki:** Validation; Writing – review & editing.

**Kazuma Ishikawa:** Writing – review & editing.

**Tatsunori Satoh:** Writing – review & editing.

**Junichi Kaneko:** Writing – review & editing.

**Junya Sato:** Writing – review & editing.

**Takamasa Oono:** Writing – review & editing.

**Kazuhide Matsumoto:** Writing – review & editing.

**Seiichiro Fukuhara:** Writing – review & editing.

**Atsuto Kayashima:** Writing – review & editing.

**Akitoshi Hakoda:** Formal analysis; Software.

**Kazuhide Higuchi:** Writing – review & editing.

**ORCID iD**

Takeshi Ogura [https://orcid.org/0000-0003-2916-6568]

**Funding**

The authors received no financial support for the research, authorship, and/or publication of this article.

**Conflict of interest statement**

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Eisuke Iwasaki is an associate editor of *Digestive*
Endoscopy. Takeshi Ogura, Hirotsoshi Ishiwatari, Nao Fujimori, Eiuke Iwasaki, Kazuma Ishikawa, Tatsunori Satoh, Junichi Kaneko, Junya Sato, Takamasa Oono, Kazuhide Matsumoto, Seichiro Fukuhara, Atsuto Kayashima, Akitoshi Hakoda, Kazuhide Higuchi have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

References

1. Fogel EL, Sherman S, Devereaux BM, et al. Therapeutic biliary endoscopy. Endoscopy 2001; 33: 31–38.
2. Williams EJ, Taylor S, Fairclough P, et al. Are we the standards set for endoscopy? Results of a large scale prospective survey of endoscopic retrograde cholangio-pancreatograph practice. Gut 2007; 56: 821–829.
3. Miller CS, Barkun AN, Martel M, et al. Endoscopic ultrasound-guided biliary drainage for distal malignant obstruction: a systematic review and meta-analysis of randomized trials. Endosc Int Open 2019; 7: E1563–E1573.
4. Katanuma A, Hayashi T, Kin T, et al. Interventional endoscopic ultrasonography in patients with surgically altered anatomy: techniques and literature review. Dig Enodsc 2020; 32: 263–274.
5. Mohan BP, Shakhatreh M, Garg R, et al. Efficacy and safety of endoscopic ultrasound-guided choledochoduodenostomy: a systematic review and meta-analysis. J Clin Gastroenterol 2019; 53: 243–250.
6. Guo J, Giovannini M, Sahai AV, et al. A multi-institution consensus on how to perform EUS-guided biliary drainage for malignant biliary obstruction. Endosc Ultrasound 2018; 7: 356–365.
7. Teoh AYB, Dhir V, Kida M, et al. Consensus guidelines on the optimal management in interventional EUS procedures: result from the Asian EUS group RAND/UCLA expert panel. Gut 2018; 67: 1209–1228.
8. Boulay BR and Lo SK. Endoscopic ultrasound-guided biliary drainage. Gastrointest Endosc Clin N Am 2018; 28: 171–183.
9. Ogura T and Higuchi K. Endoscopic ultrasound-guided gallbladder drainage: current status and future prospects. Dig Endosc 2019; 31(Suppl. 1): 55–64.
10. Law R and Baron TH. Endoscopic ultrasound-guided biliary interventions: an update on recent developments. Curr Opin Gastroenterol 2016; 32: 232–237.
11. Hathorn KE, Bazarbashi AN, Sack JS, et al. EUS-guided biliary drainage is equivalent to ERCP for primary treatment of malignant distal biliary obstruction: a systematic review and meta-analysis. Endosc Int Open 2019; 7: E1432–E1441.
12. Park JK, Woo YS, Noh DH, et al. Efficacy of EUS-guided and ERCP-guided biliary drainage for malignant biliary obstruction: prospective randomized controlled study. Gastrointest Endosc 2018; 88: 277–282.
13. Paik WH, Lee TH, Park DH, et al. EUS-guided biliary drainage versus ERCP for the primary palliation of malignant biliary obstruction: a multicenter randomized clinical trial. Am J Gastrointrol 2018; 113: 987–997.
14. World Health Organization. World health report. Geneva: World Health Organization, 2019.
15. Fritz E, Kirchgatterer A, Hubner D, et al. ERCP is safe and effective in patients 80 years of age and older compared with younger patients. Gastrointest Endosc 2006; 64: 899–905.
16. Han SJ, Lee TH, Kang BI, et al. Efficacy and safety of therapeutic endoscopic retrograde cholangiopancreatography in the elderly over 80 years. Dig Dis Sci 2016; 61: 2094–2101.
17. Tohda G, Ohtani M, Dochin M, et al. Efficacy and safety of emergency endoscopic retrograde cholangiopancreatography for acute cholangitis in the elderly. World J Gastroenterol 2016; 22: 8382–8388.
18. American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 2002; 96: 1004–1017.
19. Ramsay MA, Savege TM, Simpson BR, et al. Controlled sedation with alphaxalone-alphadolone. Br Med J 1974; 2: 656–659.
20. Oken MM, Creech RH, Torney DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655.
21. Ronen M, Weissbrod R, Overdyk FJ, et al. Smart respiratory monitoring: clinical development and validation of the IPITM (Intergrade Pulmonary Index) algorithm. J Clin Monit Comput 2017; 31: 435–442.
22. Cotton PB, Eisen GM, Aabakken L, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446–454.
23. Minaga K, Takenaka M, Kitano M, et al. Rescue EUS-guided intrahepatic biliary drainage for malignant hilar biliary stricture after failed transpapillary re-intervention. Surg Endosc 2017; 31: 4764–4772.

24. Sportes A, Camus M, Greget M, et al. Endoscopic ultrasound-guided hepaticogastrostomy versus percutaneous transhepatic drainage for malignant biliary obstruction after failed endoscopic retrograde cholangiopancreatography: a retrospective expertise-based study from two centers. Therap Adv Gastroenterol 2017; 10: 483–493.

25. Oh D, Park DH, Song TJ, et al. Optimal biliary access point and learning curve for endoscopic ultrasound-guided hepaticogastrostomy with transmural stenting. Therap Adv Gastroenterol 2017; 10: 42–53.

26. Honjo M, Itoi T, Tsuchiya T, et al. Safety and efficacy of ultra-tapered mechanical dilator for EUS-guided hepaticogastrostomy and pancreatic duct drainage compared with electrocautery dilator (with video). Endosc Ultrasound 2018; 7: 376–382.

27. Nakai Y, Sato T, Hakuta R, et al. Long-term outcomes of a long, partially covered metal stent for EUS-guided hepaticogastrostomy in patients with malignant biliary obstruction (with video). Gastrointest Endosc 2020; 92: 623–631.e1.

28. Qadeer MA, Vargo JJ, Dumot JA, et al. Capnographic monitoring of respiratory activity improves safety of sedation for endoscopic retrograde cholangiopancreatography and ultrasonography. Gastroenterology 2009; 136: 1568–1576; quiz 1819–1820.

29. Peveling-Oberhag J, Michael F, Tal A, et al. Capnography monitoring of non-anesthesiologist provided sedation during percutaneous endoscopic gastrostomy placement: a prospective, controlled, randomized trial. J Gastroenterol Hepatol 2020; 35: 401–407.

30. Klare P, Reiter J, Meining A, et al. Capnographic monitoring of midazolam and propofol sedation during ERCP: a randomized controlled study (EndoBreath Study). Endoscopy 2016; 48: 42–50.